The expression of p-EGFR and p-AKT decreased in CRC cells after DCZ0415 treatment suggesting that the anti-tumor effect of DCZ0415 was involved in the EGFR/AKT signaling pathway (Fig. 5G). The gene discussed is EGFR; the disease is colorectal carcinoma.